Pathology of Neurodegenerative Diseases

As the average life expectancy has been extended by the current state-of-art medical technologies, the elderly population is increasing rapidly. The world is now facing the ‘ageing era’, which comes with social issues like neurodegenerative diseases. Neurodegenerative diseases are progressive neurological disorders highly linked to brain injuries from which there is no recovery. Selective neuronal loss in particular regions of our brain causes different types of neurodegenerative diseases such as Alzheimer’s disease (AD), Parkinson’s disease (PD), stroke, amyotrophic lateral sclerosis (ALS), and many others. Two of the most common forms are AD and PD, and currently there are no fundamental cure available.

[1]  Alin Ciobica,et al.  The oxidative stress hypothesis in Alzheimer's disease. , 2013, Psychiatria Danubina.

[2]  A. González-Quevedo,et al.  Brain Damage - Bridging Between Basic Research and Clinics , 2012 .

[3]  K. Ashe,et al.  Cognitive effects of cell-derived and synthetically derived Aβ oligomers , 2011, Neurobiology of Aging.

[4]  P. Reddy,et al.  Abnormal tau, mitochondrial dysfunction, impaired axonal transport of mitochondria, and synaptic deprivation in Alzheimer's disease , 2011, Brain Research.

[5]  H. Hampel,et al.  Biomarker candidates of neurodegeneration in Parkinson’s disease for the evaluation of disease-modifying therapeutics , 2011, Journal of Neural Transmission.

[6]  A. I. Rojo,et al.  Pharmacological targeting of the transcription factor Nrf2 at the basal ganglia provides disease modifying therapy for experimental parkinsonism. , 2011, Antioxidants & redox signaling.

[7]  A. Schapira,et al.  Etiology and pathogenesis of Parkinson's disease , 2011, Movement disorders : official journal of the Movement Disorder Society.

[8]  A. Schapira,et al.  Mitochondrial Contribution to Parkinson's Disease Pathogenesis , 2011, Parkinson's disease.

[9]  Jau-Shyong Hong,et al.  Neuroinflammation and α-Synuclein Dysfunction Potentiate Each Other, Driving Chronic Progression of Neurodegeneration in a Mouse Model of Parkinson’s Disease , 2011, Environmental health perspectives.

[10]  Eun-mee Kim,et al.  Role of matrix metalloproteinase‐3 in neurodegeneration , 2011, Journal of neurochemistry.

[11]  Armin Giese,et al.  Inhibition of mitochondrial fusion by α‐synuclein is rescued by PINK1, Parkin and DJ‐1 , 2010, The EMBO journal.

[12]  David S. Park,et al.  Loss of the Parkinson's disease-linked gene DJ-1 perturbs mitochondrial dynamics. , 2010, Human molecular genetics.

[13]  K. Lohmann,et al.  Mutant Parkin Impairs Mitochondrial Function and Morphology in Human Fibroblasts , 2010, PloS one.

[14]  A. Dinkova-Kostova,et al.  NAD(P)H:quinone acceptor oxidoreductase 1 (NQO1), a multifunctional antioxidant enzyme and exceptionally versatile cytoprotector. , 2010, Archives of biochemistry and biophysics.

[15]  A. I. Rojo,et al.  Different Susceptibility to the Parkinson's Toxin MPTP in Mice Lacking the Redox Master Regulator Nrf2 or Its Target Gene Heme Oxygenase-1 , 2010, PloS one.

[16]  Hee-Sun Kim,et al.  α-Synuclein Activates Microglia by Inducing the Expressions of Matrix Metalloproteinases and the Subsequent Activation of Protease-Activated Receptor-1 , 2010, The Journal of Immunology.

[17]  Jau-Shyong Hong,et al.  Neuroinflammation is a key player in Parkinson’s disease and a prime target for therapy , 2010, Journal of Neural Transmission.

[18]  M. Farrer,et al.  Missing pieces in the Parkinson's disease puzzle , 2010, Nature Medicine.

[19]  T. Joh,et al.  Matrix Metalloproteinase-3 Is Increased and Participates in Neuronal Apoptotic Signaling Downstream of Caspase-12 during Endoplasmic Reticulum Stress* , 2010, The Journal of Biological Chemistry.

[20]  C. Jack,et al.  Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade , 2010, The Lancet Neurology.

[21]  Yusuke Nakamura,et al.  Genome-wide association study identifies common variants at four loci as genetic risk factors for Parkinson's disease , 2009, Nature Genetics.

[22]  Sonja W. Scholz,et al.  Genome-Wide Association Study reveals genetic risk underlying Parkinson’s disease , 2009, Nature Genetics.

[23]  J. Trojanowski,et al.  Advances in tau-focused drug discovery for Alzheimer's disease and related tauopathies , 2009, Nature Reviews Drug Discovery.

[24]  Sehee Kim,et al.  Exendin-4 protects dopaminergic neurons by inhibition of microglial activation and matrix metalloproteinase-3 expression in an animal model of Parkinson's disease. , 2009, The Journal of endocrinology.

[25]  Connie Marras,et al.  Occupation and risk of parkinsonism: a multicenter case-control study. , 2009, Archives of neurology.

[26]  F. Chiti,et al.  Kinetic Analysis of Amyloid Formation in the Presence of Heparan Sulfate , 2009, The Journal of Biological Chemistry.

[27]  T. Joh,et al.  Doxycycline is Neuroprotective Against Nigral Dopaminergic Degeneration by a Dual Mechanism Involving MMP-3 , 2009, Neurotoxicity Research.

[28]  H. Ariga,et al.  Kaempferol derivatives prevent oxidative stress-induced cell death in a DJ-1-dependent manner. , 2009, Journal of pharmacological sciences.

[29]  M. Cascio,et al.  Proteomic identification of dopamine-conjugated proteins from isolated rat brain mitochondria and SH-SY5Y cells , 2009, Neurobiology of Disease.

[30]  C. Warren Olanow,et al.  The scientific and clinical basis for the treatment of Parkinson disease (2009) , 2009, Neurology.

[31]  M. S. Jafri,et al.  Nrf2 activators provide neuroprotection against 6‐hydroxydopamine toxicity in rat organotypic nigrostriatal cocultures , 2009, Journal of neuroscience research.

[32]  K. Chaudhuri,et al.  Non-motor symptoms of Parkinson's disease: dopaminergic pathophysiology and treatment , 2009, The Lancet Neurology.

[33]  Hong Zhu,et al.  Cruciferous Nutraceutical 3H-1,2-dithiole-3-thione Protects Human Primary Astrocytes Against Neurocytotoxicity Elicited by MPTP, MPP+, 6-OHDA, HNE and Acrolein , 2009, Neurochemical Research.

[34]  Xin Li,et al.  α-Synuclein is differentially expressed in mitochondria from different rat brain regions and dose-dependently down-regulates complex I activity , 2009, Neuroscience Letters.

[35]  R. King,et al.  Differential effects of PINK1 nonsense and missense mutations on mitochondrial function and morphology , 2009, Experimental Neurology.

[36]  M. Oh,et al.  Neuroprotective Effect of Ghrelin in the 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine Mouse Model of Parkinson’s Disease by Blocking Microglial Activation , 2009, Neurotoxicity Research.

[37]  Michael R. Duchen,et al.  PINK1-Associated Parkinson's Disease Is Caused by Neuronal Vulnerability to Calcium-Induced Cell Death , 2009, Molecular cell.

[38]  L. Petrucelli,et al.  Molecular Neurodegeneration BioMed Central , 2009 .

[39]  J. Cooper,et al.  Silencing of PINK1 Expression Affects Mitochondrial DNA and Oxidative Phosphorylation in DOPAMINERGIC Cells , 2009, PloS one.

[40]  J. Downward,et al.  Mitochondrial dysfunction triggered by loss of HtrA2 results in the activation of a brain-specific transcriptional stress response , 2009, Cell Death and Differentiation.

[41]  D. Jennings,et al.  Can we image premotor Parkinson disease? , 2009, Neurology.

[42]  Dong Jin Kim,et al.  Multivalent & Multifunctional Ligands to β-Amyloid , 2009 .

[43]  D. Simon,et al.  Transcribe to survive: transcriptional control of antioxidant defense programs for neuroprotection in Parkinson's disease. , 2009, Antioxidants & redox signaling.

[44]  E. Sulkowski,et al.  Alzheimer's β-amyloid peptide: affinity for metal chelates , 2009 .

[45]  S. Przedborski,et al.  Oxidative Stress in Parkinson's Disease , 2008, Annals of the New York Academy of Sciences.

[46]  Erika K Wallender,et al.  Optical Reporters for the Conformation of α-Synuclein Reveal a Specific Interaction with Mitochondria , 2008, The Journal of Neuroscience.

[47]  W. Ju,et al.  Mpv17l protects against mitochondrial oxidative stress and apoptosis by activation of Omi/HtrA2 protease , 2008, Proceedings of the National Academy of Sciences.

[48]  J. Trojanowski,et al.  Neuroinflammation and Oxidation/Nitration of α-Synuclein Linked to Dopaminergic Neurodegeneration , 2008, The Journal of Neuroscience.

[49]  T. Joh,et al.  A novel intracellular role of matrix metalloproteinase‐3 during apoptosis of dopaminergic cells , 2008, Journal of neurochemistry.

[50]  Hee-Sun Kim,et al.  Inhibition of MMP‐3 or ‐9 suppresses lipopolysaccharide‐induced expression of proinflammatory cytokines and iNOS in microglia , 2008, Journal of neurochemistry.

[51]  P. Emson,et al.  Altered vesicular dopamine storage in Parkinson's disease: a premature demise , 2008, Trends in Neurosciences.

[52]  Ninds Net-Pd Investigators.  A Pilot Clinical Trial of Creatine and Minocycline in Early Parkinson Disease: 18-Month Results , 2008, Clinical neuropharmacology.

[53]  N. Avadhani,et al.  Mitochondrial Import and Accumulation of α-Synuclein Impair Complex I in Human Dopaminergic Neuronal Cultures and Parkinson Disease Brain* , 2008, Journal of Biological Chemistry.

[54]  G. Zeevalk,et al.  Glutathione and Parkinson's disease: is this the elephant in the room? , 2008, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[55]  G. Deuschl,et al.  Human neuromelanin induces neuroinflammation and neurodegeneration in the rat substantia nigra: implications for Parkinson's disease , 2008, Acta Neuropathologica.

[56]  Hong Zhu,et al.  Potent induction of total cellular GSH and NQO1 as well as mitochondrial GSH by 3H-1,2-dithiole-3-thione in SH-SY5Y neuroblastoma cells and primary human neurons: Protection against neurocytotoxicity elicited by dopamine, 6-hydroxydopamine, 4-hydroxy-2-nonenal, or hydrogen peroxide , 2008, Brain Research.

[57]  W. Thies,et al.  2008 Alzheimer’s disease facts and figures , 2008, Alzheimer's & Dementia.

[58]  Peter T Lansbury,et al.  Dopamine-modified alpha-synuclein blocks chaperone-mediated autophagy. , 2008, The Journal of clinical investigation.

[59]  B. Cagniard,et al.  Unregulated Cytosolic Dopamine Causes Neurodegeneration Associated with Oxidative Stress in Mice , 2008, The Journal of Neuroscience.

[60]  H. Gendelman,et al.  Nitrated α–Synuclein Immunity Accelerates Degeneration of Nigral Dopaminergic Neurons , 2008, PloS one.

[61]  M. Sullivan.  Tramiprosate Falls Short in Phase III Alzheimer's Trial , 2007 .

[62]  T. Dawson,et al.  DJ-1 gene deletion reveals that DJ-1 is an atypical peroxiredoxin-like peroxidase , 2007, Proceedings of the National Academy of Sciences.

[63]  J. Ávila,et al.  Tramiprosate, a drug of potential interest for the treatment of Alzheimer's disease, promotes an abnormal aggregation of tau , 2007, Molecular Neurodegeneration.

[64]  D. Ross,et al.  A comparative study of proteasomal inhibition and apoptosis induced in N27 mesencephalic cells by dopamine and MG132 , 2007, Journal of neurochemistry.

[65]  Sandra E. Black.  S3–02–02: Flurizan , 2007 .

[66]  Michael P. Mazanetz,et al.  Untangling tau hyperphosphorylation in drug design for neurodegenerative diseases , 2007, Nature Reviews Drug Discovery.

[67]  M. Verbeek,et al.  Heat Shock Proteins and Amateur Chaperones in Amyloid-Beta Accumulation and Clearance in Alzheimer’s Disease , 2007, Molecular Neurobiology.

[68]  I. Melnikova.  Therapies for Alzheimer's disease , 2007, Nature Reviews Drug Discovery.

[69]  K. Sakumi,et al.  Oxidative damage in nucleic acids and Parkinson's disease , 2007, Journal of neuroscience research.

[70]  Ha Won Kim,et al.  Protective Effect of Sulforaphane against Dopaminergic Cell Death , 2007, Journal of Pharmacology and Experimental Therapeutics.

[71]  C. Morissette,et al.  Targeting soluble Aβ peptide with Tramiprosate for the treatment of brain amyloidosis , 2007, Neurobiology of Aging.

[72]  C. Farina,et al.  Astrocytes are active players in cerebral innate immunity. , 2007, Trends in immunology.

[73]  Dwight C. German,et al.  Mitochondria mass is low in mouse substantia nigra dopamine neurons: Implications for Parkinson's disease , 2007, Experimental Neurology.

[74]  J. Jankovic,et al.  A randomized clinical trial of coenzyme Q10 and GPI-1485 in early Parkinson disease , 2007, Neurology.

[75]  S. Lorenzl,et al.  A pivotal role of matrix metalloproteinase‐3 activity in dopaminergic neuronal degeneration via microglial activation , 2007, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[76]  W. Szarek,et al.  Heparan sulfate as a therapeutic target in amyloidogenesis: prospects and possible complications , 2007, Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis.

[77]  A. Blair,et al.  Pesticide exposure and self-reported Parkinson's disease in the agricultural health study. , 2006, American journal of epidemiology.

[78]  D. Ross,et al.  Overexpression of NQO1 protects human SK-N-MC neuroblastoma cells against dopamine-induced cell death. , 2006, Toxicology letters.

[79]  D. Ross,et al.  A Potential Role for Cyclized Quinones Derived from Dopamine, DOPA, and 3,4-Dihydroxyphenylacetic Acid in Proteasomal Inhibition , 2006, Molecular Pharmacology.

[80]  I. Ferrer,et al.  Amyloid-β Peptide Remnants in AN-1792-Immunized Alzheimer's Disease Patients: A Biochemical Analysis , 2006 .

[81]  G. Rosenberg,et al.  Blood–brain barrier disruption by stromelysin-1 facilitates neutrophil infiltration in neuroinflammation , 2006, Neurobiology of Disease.

[82]  Sunhong Kim,et al.  Mitochondrial dysfunction in Drosophila PINK1 mutants is complemented by parkin , 2006, Nature.

[83]  Changan Jiang,et al.  Drosophila pink1 is required for mitochondrial function and interacts genetically with parkin , 2006, Nature.

[84]  K. Ono,et al.  Anti-amyloidogenic therapies: strategies for prevention and treatment of Alzheimer’s disease , 2006, Cellular and Molecular Life Sciences CMLS.

[85]  O. Livnah,et al.  Butyrylcholinesterase attenuates amyloid fibril formation in vitro. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[86]  Tsuyoshi Hamaguchi,et al.  Anti-amyloidogenic effects of antioxidants: implications for the prevention and therapeutics of Alzheimer's disease. , 2006, Biochimica et biophysica acta.

[87]  H. Kozłowski,et al.  Copper homeostasis and neurodegenerative disorders (Alzheimer's, prion, and Parkinson's diseases and amyotrophic lateral sclerosis). , 2006, Chemical reviews.

[88]  L. Mucke,et al.  PKCε increases endothelin converting enzyme activity and reduces amyloid plaque pathology in transgenic mice , 2006 .

[89]  R. Lerner,et al.  Elevated levels of oxidized cholesterol metabolites in Lewy body disease brains accelerate α-synuclein fibrilization , 2006, Nature chemical biology.

[90]  M. Cameron Sullards,et al.  Oxidative Damage of DJ-1 Is Linked to Sporadic Parkinson and Alzheimer Diseases* , 2006, Journal of Biological Chemistry.

[91]  Robert W. Taylor,et al.  High levels of mitochondrial DNA deletions in substantia nigra neurons in aging and Parkinson disease , 2006, Nature Genetics.

[92]  M. Farrer.  Genetics of Parkinson disease: paradigm shifts and future prospects , 2006, Nature Reviews Genetics.

[93]  K. Kitaichi,et al.  Methamphetamine‐induced dopaminergic neurotoxicity is regulated by quinone formation‐related molecules , 2006, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[94]  Alexander Hammers,et al.  In vivo imaging of microglial activation with [11C](R)-PK11195 PET in idiopathic Parkinson's disease , 2006, Neurobiology of Disease.

[95]  D. Price,et al.  Parkinson's Disease α-Synuclein Transgenic Mice Develop Neuronal Mitochondrial Degeneration and Cell Death , 2006, The Journal of Neuroscience.

[96]  T. Montine,et al.  Deletion of the Prostaglandin E2 EP2 Receptor Reduces Oxidative Damage and Amyloid Burden in a Model of Alzheimer's Disease , 2005, The Journal of Neuroscience.

[97]  L. Mucke,et al.  Fyn Kinase Induces Synaptic and Cognitive Impairments in a Transgenic Mouse Model of Alzheimer's Disease , 2005, The Journal of Neuroscience.

[98]  D. Selkoe,et al.  Dopamine covalently modifies and functionally inactivates parkin , 2005, Nature Medicine.

[99]  Sanjay Gupta,et al.  A review of antioxidants and Alzheimer's disease. , 2005, Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists.

[100]  Jane Y. Wu,et al.  Tau Alternative Splicing and Frontotemporal Dementia , 2005, Alzheimer disease and associated disorders.

[101]  J. Schulz,et al.  Loss of function mutations in the gene encoding Omi/HtrA2 in Parkinson's disease. , 2005, Human molecular genetics.

[102]  G. Rosenberg,et al.  Matrix metalloproteinases and free radicals in cerebral ischemia. , 2005, Free radical biology & medicine.

[103]  Smita Patel,et al.  Intravesicular Localization and Exocytosis of α-Synuclein and its Aggregates , 2005, The Journal of Neuroscience.

[104]  Ali Samii,et al.  Intake of vitamin E, vitamin C, and carotenoids and the risk of Parkinson's disease: a meta-analysis , 2005, The Lancet Neurology.

[105]  D. Teplow,et al.  On the nucleation of amyloid β‐protein monomer folding , 2005 .

[106]  Jianpeng Ma,et al.  Conformational transition of amyloid β-peptide , 2005 .

[107]  T. Joh,et al.  Matrix Metalloproteinase-3: A Novel Signaling Proteinase from Apoptotic Neuronal Cells That Activates Microglia , 2005, The Journal of Neuroscience.

[108]  Belinda Wilson,et al.  Aggregated α‐synuclein activates microglia: a process leading to disease progression in Parkinson's disease , 2005, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[109]  W. Longstreth,et al.  No associations between Parkinson's disease and polymorphisms of the quinone oxidoreductase (NQO1, NQO2) genes , 2005, Neuroscience Letters.

[110]  A. Andreadis.  Tau gene alternative splicing: expression patterns, regulation and modulation of function in normal brain and neurodegenerative diseases. , 2005, Biochimica et biophysica acta.

[111]  I. Grundke‐Iqbal,et al.  Tau pathology in Alzheimer disease and other tauopathies. , 2005, Biochimica et biophysica acta.

[112]  Robert W Berry,et al.  Tau, tangles, and Alzheimer's disease. , 2005, Biochimica et biophysica acta.

[113]  N. Shahani,et al.  Tau alteration and neuronal degeneration in tauopathies: mechanisms and models. , 2005, Biochimica et biophysica acta.

[114]  Thomas Meitinger,et al.  Mutations in LRRK2 Cause Autosomal-Dominant Parkinsonism with Pleomorphic Pathology , 2004, Neuron.

[115]  Andrew Lees,et al.  Cloning of the Gene Containing Mutations that Cause PARK8-Linked Parkinson's Disease , 2004, Neuron.

[116]  Sebastian Brandner,et al.  Neuroprotective Role of the Reaper-Related Serine Protease HtrA2/Omi Revealed by Targeted Deletion in Mice , 2004, Molecular and Cellular Biology.

[117]  J. Bol,et al.  Expression of NAD(P)H:quinone oxidoreductase in the normal and Parkinsonian substantia nigra , 2004, Neurobiology of Aging.

[118]  M. Vila,et al.  MPTP as a Mitochondrial Neurotoxic Model of Parkinson's Disease , 2004, Journal of bioenergetics and biomembranes.

[119]  P. Doraiswamy,et al.  Metals in our minds: therapeutic implications for neurodegenerative disorders , 2004, The Lancet Neurology.

[120]  J. Andersen,et al.  Oxidative stress in neurodegeneration: cause or consequence? , 2004, Nature Reviews Neuroscience.

[121]  David W. Miller,et al.  The Parkinson's disease protein DJ-1 is neuroprotective due to cysteine-sulfinic acid-driven mitochondrial localization , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[122]  Jesús Avila,et al.  Glycogen synthase kinase 3: a drug target for CNS therapies , 2004, Journal of neurochemistry.

[123]  M. Müftüoğlu,et al.  Mitochondrial complex I and IV activities in leukocytes from patients with parkin mutations , 2004, Movement disorders : official journal of the Movement Disorder Society.

[124]  D. Teplow,et al.  Small assemblies of unmodified amyloid β-protein are the proximate neurotoxin in Alzheimer’s disease , 2004, Neurobiology of Aging.

[125]  Joachim Klose,et al.  Mitochondrial Dysfunction and Oxidative Damage in parkin-deficient Mice* , 2004, Journal of Biological Chemistry.

[126]  J. L. Stringer,et al.  Presence and induction of the enzyme NAD(P)H: Quinone oxidoreductase 1 in the central nervous system , 2004, The Journal of comparative neurology.

[127]  G. Johnson,et al.  Cyclin‐dependent kinase‐5 in neurodegeneration , 2004, Journal of neurochemistry.

[128]  Biao Chen,et al.  [A study on the relationship between polymorphism of human NAD(P)H: quinone oxidoreductase and Parkinson's disease in Chinese]. , 2004, Zhonghua yi xue yi chuan xue za zhi = Zhonghua yixue yichuanxue zazhi = Chinese journal of medical genetics.

[129]  Allan I. Levey,et al.  Oxidative Modifications and Down-regulation of Ubiquitin Carboxyl-terminal Hydrolase L1 Associated with Idiopathic Parkinson's and Alzheimer's Diseases* , 2004, Journal of Biological Chemistry.

[130]  G. V. Van Hoesen,et al.  Phosphorylation of Tau by Fyn: Implications for Alzheimer's Disease , 2004, The Journal of Neuroscience.

[131]  D. Selkoe,et al.  Alzheimer's disease: molecular understanding predicts amyloid-based therapeutics. , 2003, Annual review of pharmacology and toxicology.

[132]  M. Ohta,et al.  Increase of antioxidative potential by tert-butylhydroquinone protects against cell death associated with 6-hydroxydopamine-induced oxidative stress in neuroblastoma SH-SY5Y cells. , 2003, Brain research. Molecular brain research.

[133]  D. Pogocki,et al.  Free radical reactions of methionine in peptides: mechanisms relevant to beta-amyloid oxidation and Alzheimer's disease. , 2003, Journal of the American Chemical Society.

[134]  S. Srinivasula,et al.  Loss of Omi mitochondrial protease activity causes the neuromuscular disorder of mnd2 mutant mice , 2003, Nature.

[135]  B. Oostra,et al.  DJ-1( PARK7), a novel gene for autosomal recessive, early onset parkinsonism , 2003, Neurological Sciences.

[136]  M. Cookson,et al.  α‐Synuclein implicated in Parkinson's disease is present in extracellular biological fluids, including human plasma , 2003, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[137]  C. Masters,et al.  Copper, β-amyloid, and Alzheimer's disease: Tapping a sensitive connection , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[138]  T. Bayer,et al.  Alzheimer β-Amyloid Homodimers Facilitate Aβ Fibrillization and the Generation of Conformational Antibodies* , 2003, Journal of Biological Chemistry.

[139]  R. Berry,et al.  Caspase cleavage of tau: Linking amyloid and neurofibrillary tangles in Alzheimer's disease , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[140]  S. Lee,et al.  Dopamine‐dependent cytotoxicity of tetrahydrobiopterin: a possible mechanism for selective neurodegeneration in Parkinson's disease , 2003, Journal of neurochemistry.

[141]  K. Davis,et al.  Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial. , 2003, JAMA.

[142]  T. Hirokawa,et al.  Alterations of structure and hydrolase activity of parkinsonism-associated human ubiquitin carboxyl-terminal hydrolase L1 variants. , 2003, Biochemical and biophysical research communications.

[143]  Carl W. Cotman,et al.  Common Structure of Soluble Amyloid Oligomers Implies Common Mechanism of Pathogenesis , 2003, Science.

[144]  G. Krafft,et al.  In Vitro Characterization of Conditions for Amyloid-β Peptide Oligomerization and Fibrillogenesis* , 2003, The Journal of Biological Chemistry.

[145]  K. Mohanakumar,et al.  Non-steroidal anti-inflammatory drug sodium salicylate, but not diclofenac or celecoxib, protects against 1-methyl-4-phenyl pyridinium-induced dopaminergic neurotoxicity in rats , 2003, Brain Research.

[146]  J. C. Greene,et al.  Mitochondrial pathology and apoptotic muscle degeneration in Drosophila parkin mutants , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[147]  E. Hirsch,et al.  Parkin prevents mitochondrial swelling and cytochrome c release in mitochondria-dependent cell death. , 2003, Human molecular genetics.

[148]  G. Deuschl,et al.  Activation of microglia by human neuromelanin is NF‐κB‐dependent and involves p38 mitogen‐activated protein kinase: implications for Parkinson's disease , 2003, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[149]  V. Andrisano,et al.  beta-Amyloid aggregation induced by human acetylcholinesterase: inhibition studies. , 2003, Biochemical pharmacology.

[150]  C. Geula,et al.  Neurobiology of butyrylcholinesterase , 2003, Nature Reviews Neuroscience.

[151]  R. Edwards.  Faculty Opinions recommendation of Resistance of alpha -synuclein null mice to the parkinsonian neurotoxin MPTP. , 2002 .

[152]  L. Tsai,et al.  A survey of Cdk5 activator p35 and p25 levels in Alzheimer's disease brains , 2002, FEBS letters.

[153]  E. Giacobini,et al.  Inhibition of acetyl- and butyryl-cholinesterase in the cerebrospinal fluid of patients with Alzheimer's disease by rivastigmine: correlation with cognitive benefit , 2002, Journal of Neural Transmission.

[154]  D. Butterfield,et al.  Methionine residue 35 is critical for the oxidative stress and neurotoxic properties of Alzheimer’s amyloid β-peptide 1–42 , 2002, Peptides.

[155]  Kirk W. Johnson,et al.  Inhibition of glycogen synthase kinase 3 improves insulin action and glucose metabolism in human skeletal muscle. , 2002, Diabetes.

[156]  L. Tsai,et al.  Colocalization and Fluorescence Resonance Energy Transfer between cdk5 and AT8 Suggests a Close Association in Pre‐Neurofibrillary Tangles and Neurofibrillary Tangles , 2002, Journal of neuropathology and experimental neurology.

[157]  S. Ferreira,et al.  Physiopathological modulators of amyloid aggregation and novel pharmacological approaches in Alzheimer's disease. , 2002, Anais da Academia Brasileira de Ciencias.

[158]  Chung-Soo Lee,et al.  Differential effect of catecholamines and MPP+ on membrane permeability in brain mitochondria and cell viability in PC12 cells , 2002, Neurochemistry International.

[159]  Dong-Kug Choi,et al.  Blockade of Microglial Activation Is Neuroprotective in the 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine Mouse Model of Parkinson Disease , 2002, The Journal of Neuroscience.

[160]  R. Bullock.  New drugs for Alzheimer's disease and other dementias , 2002, British Journal of Psychiatry.

[161]  P. Andrade-Gordon,et al.  Participation of protease‐activated receptor‐1 in thrombin‐induced microglial activation , 2002, Journal of neurochemistry.

[162]  P. Camps,et al.  Cholinergic drugs in pharmacotherapy of Alzheimer's disease. , 2002, Mini reviews in medicinal chemistry.

[163]  J. Flier,et al.  The Neuroprotective Antioxidant α-lipoic Acid Induces Detoxication Enzymes in Cultured Astroglial Cells , 2002, Free radical research.

[164]  Taku Sugawara,et al.  Matrix Metalloproteinase Inhibition Prevents Oxidative Stress-Associated Blood–Brain Barrier Disruption after Transient Focal Cerebral Ischemia , 2001, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[165]  D. Butterfield,et al.  Evidence of oxidative damage in Alzheimer's disease brain: central role for amyloid beta-peptide. , 2001, Trends in molecular medicine.

[166]  D. Allsop,et al.  Production of reactive oxygen species from aggregating proteins implicated in Alzheimer's disease, Parkinson's disease and other neurodegenerative diseases. , 2001, Current topics in medicinal chemistry.

[167]  S. Paul,et al.  Minocycline prevents nigrostriatal dopaminergic neurodegeneration in the MPTP model of Parkinson's disease , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[168]  S. Harada,et al.  An association between idiopathic Parkinson's disease and polymorphisms of phase II detoxification enzymes: glutathione S-transferase M1 and quinone oxidoreductase 1 and 2. , 2001, Biochemical and biophysical research communications.

[169]  Peter T. Lansbury,et al.  Kinetic Stabilization of the α-Synuclein Protofibril by a Dopamine-α-Synuclein Adduct , 2001, Science.

[170]  Li-Huei Tsai,et al.  A decade of CDK5 , 2001, Nature Reviews Molecular Cell Biology.

[171]  I Silman,et al.  A structural motif of acetylcholinesterase that promotes amyloid beta-peptide fibril formation. , 2001, Biochemistry.

[172]  G. Pasinetti,et al.  Cyclooxygenase and Alzheimer's disease: implications for preventive initiatives to slow the progression of clinical dementia. , 2001, Archives of gerontology and geriatrics.

[173]  W. Willett,et al.  Prospective study of caffeine consumption and risk of Parkinson's disease in men and women , 2001, Annals of neurology.

[174]  L. Amzel,et al.  Mechanism of NAD(P)H:Quinone reductase: Ab initio studies of reduced flavin , 2001, Proteins.

[175]  C. Masters,et al.  Treatment with a Copper-Zinc Chelator Markedly and Rapidly Inhibits β-Amyloid Accumulation in Alzheimer's Disease Transgenic Mice , 2001, Neuron.

[176]  B. Fiebich,et al.  Minocycline, a Tetracycline Derivative, Is Neuroprotective against Excitotoxicity by Inhibiting Activation and Proliferation of Microglia , 2001, The Journal of Neuroscience.

[177]  I. Ferrer,et al.  Phosphorylated Map Kinase (ERK1, ERK2) Expression is Associated with Early Tau Deposition in Neurones and Glial Cells, but not with Increased Nuclear DNA Vulnerability and Cell Death, in Alzheimer Disease, Pick's Disease, Progressive Supranuclear Palsy and Corticobasal Degeneration , 2001, Brain pathology.

[178]  M. Michikawa,et al.  Site-specific Phosphorylation of Tau Accompanied by Activation of Mitogen-activated Protein Kinase (MAPK) in Brains of Niemann-Pick Type C Mice* , 2001, The Journal of Biological Chemistry.

[179]  Xiaoxiang Zhu,et al.  A New Therapeutic Target in Alzheimer's Disease Treatment: Attention to Butyrylcholinesterase , 2001, Current medical research and opinion.

[180]  M. Mercken,et al.  Glycogen Synthase Kinase-3β Phosphorylates Protein Tau and Rescues the Axonopathy in the Central Nervous System of Human Four-repeat Tau Transgenic Mice* , 2000, The Journal of Biological Chemistry.

[181]  G. Wilcock,et al.  Efficacy and safety of galantamine in patients with mild to moderate Alzheimer's disease: multicentre randomised controlled trial , 2000, BMJ : British Medical Journal.

[182]  G. Wilkin,et al.  Inflammatory Regulators in Parkinson's Disease: iNOS, Lipocortin-1, and Cyclooxygenases-1 and -2 , 2000, Molecular and Cellular Neuroscience.

[183]  Todd B. Sherer,et al.  Chronic systemic pesticide exposure reproduces features of Parkinson's disease , 2000, Nature Neuroscience.

[184]  T. Dawson,et al.  Parkin functions as an E2-dependent ubiquitin- protein ligase and promotes the degradation of the synaptic vesicle-associated protein, CDCrel-1. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[185]  P. Fraser,et al.  Effect of amino-acid substitutions on Alzheimer's amyloid-beta peptide-glycosaminoglycan interactions. , 2000, European journal of biochemistry.

[186]  T. Hastings,et al.  Role of oxidative changes in the degeneration of dopamine terminals after injection of neurotoxic levels of dopamine , 2000, Neuroscience.

[187]  K. Ashe,et al.  Ibuprofen Suppresses Plaque Pathology and Inflammation in a Mouse Model for Alzheimer's Disease , 2000, The Journal of Neuroscience.

[188]  A. Jaiswal,et al.  Role of NAD(P)H:quinone oxidoreductase 1 (DT diaphorase) in protection against quinone toxicity. , 2000, Biochemical pharmacology.

[189]  M. Tabaton,et al.  Full length α-synuclein is present in cerebrospinal fluid from Parkinson's disease and normal subjects , 2000, Neuroscience Letters.

[190]  J. Trojanowski,et al.  In vivo detection of amyloid plaques in a mouse model of Alzheimer's disease , 2000, Neurobiology of Aging.

[191]  S. Hirai,et al.  Age‐related amyloid β protein accumulation induces cellular death and macrophage activation in transgenic mice , 2000 .

[192]  G. Ugolini,et al.  The neuronal microtubule associated protein tau is a substrate for caspase-3 and an effector of apoptosis , 2000, Neurobiology of Aging.

[193]  M. Hutton.  Molecular genetics of chromosome 17 tauopathies , 2000, Neurobiology of Aging.

[194]  M. Jann,et al.  Rivastigmine, a New‐Generation Cholinesterase Inhibitor for the Treatment of Alzheimer's Disease , 2000, Pharmacotherapy.

[195]  Claire Shepherd,et al.  Alzheimer’s Disease And Inflammation: A Review Of Cellular And Therapeutic Mechanisms , 2000, Clinical and experimental pharmacology & physiology.

[196]  P. Fraser,et al.  Interactions of Alzheimer amyloid-beta peptides with glycosaminoglycans effects on fibril nucleation and growth. , 1999, European journal of biochemistry.

[197]  J. Langston,et al.  Evidence of active nerve cell degeneration in the substantia nigra of humans years after 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine exposure , 1999, Annals of neurology.

[198]  L. Elferink,et al.  Tyrosine Hydroxylase Is Inactivated by Catechol‐Quinones and Converted to a Redox‐Cycling Quinoprotein , 1999, Journal of neurochemistry.

[199]  S. Berman,et al.  Dopamine Oxidation Alters Mitochondrial Respiration and Induces Permeability Transition in Brain Mitochondria , 1999, Journal of neurochemistry.

[200]  N. Holbrook,et al.  Activation of neuronal extracellular receptor kinase (ERK) in Alzheimer disease links oxidative stress to abnormal phosphorylation. , 1999, Neuroreport.

[201]  R. Motter,et al.  Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse , 1999, Nature.

[202]  C. Barrow,et al.  Histidine-13 is a crucial residue in the zinc ion-induced aggregation of the A beta peptide of Alzheimer's disease. , 1999, Biochemistry.

[203]  Anders Björklund,et al.  Prospects for new restorative and neuroprotective treatments in Parkinson's disease , 1999, Nature.

[204]  Schumann,et al.  Anti-inflammatory substances - a new therapeutic option in Alzheimer's disease. , 1999, Drug discovery today.

[205]  N. Inestrosa,et al.  Neurotoxicity of acetylcholinesterase amyloid β‐peptide aggregates is dependent on the type of Aβ peptide and the AChE concentration present in the complexes , 1999, FEBS letters.

[206]  A. Clark,et al.  Elevated neuronal Cdc2-like kinase activity in the Alzheimer disease brain , 1999, Neuroscience Research.

[207]  P. Mcgeer,et al.  Inflammation of the brain in Alzheimer's disease: implications for therapy , 1999, Journal of leukocyte biology.

[208]  T. Wight,et al.  The Sulfate Moieties of Glycosaminoglycans Are Critical for the Enhancement of β‐Amyloid Protein Fibril Formation , 1999, Journal of neurochemistry.

[209]  M. Hutton,et al.  Accelerated filament formation from tau protein with specific FTDP‐17 missense mutations , 1999, FEBS letters.

[210]  S. Lovestone,et al.  Mutations in tau reduce its microtubule binding properties in intact cells and affect its phosphorylation , 1999, FEBS letters.

[211]  A. Członkowska,et al.  The Inflammatory Reaction Following 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine Intoxication in Mouse , 1999, Experimental Neurology.

[212]  C. Behl.  Alzheimer's disease and oxidative stress: implications for novel therapeutic approaches , 1999, Progress in Neurobiology.

[213]  John X. Morris,et al.  Mutation-specific functional impairments in distinct tau isoforms of hereditary FTDP-17. , 1998, Science.

[214]  A. Lees,et al.  Conjugates of Catecholamines with Cysteine and GSH in Parkinson's Disease: Possible Mechanisms of Formation Involving Reactive Oxygen Species , 1998, Journal of neurochemistry.

[215]  M. Goedert,et al.  Tau proteins with FTDP‐17 mutations have a reduced ability to promote microtubule assembly , 1998, FEBS letters.

[216]  P. Libby,et al.  Generation of Biologically Active IL-1β by Matrix Metalloproteinases: A Novel Caspase-1-Independent Pathway of IL-1β Processing , 1998, The Journal of Immunology.

[217]  Hitoshi Takahashi,et al.  Clinical and neuropathological aspects of autosomal recessive juvenile parkinsonism , 1998, Journal of Neurology.

[218]  N. Delanty,et al.  Risk of Alzheimer's disease and duration of NSAID use , 1998, Neurology.

[219]  D. Riesner,et al.  Detection of single amyloid β-protein aggregates in the cerebrospinal fluid of Alzheimer's patients by fluorescence correlation spectroscopy , 1998, Nature Medicine.

[220]  T. Murphy,et al.  Activation of Endogenous Antioxidant Defenses in Neuronal Cells Prevents Free Radical‐Mediated Damage , 1998, Journal of neurochemistry.

[221]  A Klug,et al.  Mutation in the tau gene in familial multiple system tauopathy with presenile dementia. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[222]  Ronald C. Petersen,et al.  Association of missense and 5′-splice-site mutations in tau with the inherited dementia FTDP-17 , 1998, Nature.

[223]  G. Schellenberg,et al.  Tau is a candidate gene for chromosome 17 frontotemporal dementia , 1998, Annals of neurology.

[224]  R. Mohs,et al.  Donepezil improves cognition and global function in Alzheimer disease: a 15-week, double-blind, placebo-controlled study. Donepezil Study Group. , 1998, Archives of internal medicine.

[225]  R. F. Shore,et al.  Diorthosubstituted Polychlorinated Biphenyls in Caudate Nucleus in Parkinson's Disease , 1998, Experimental Neurology.

[226]  S. Daniel,et al.  Glial pathology but absence of apoptotic nigral neurons in long‐standing Parkinson's disease , 1998, Movement disorders : official journal of the Movement Disorder Society.

[227]  T. Wight,et al.  Perlecan Binds to the β‐Amyloid Proteins (Aβ) of Alzheimer's Disease, Accelerates Aβ Fibril Formation, and Maintains Aβ Fibril Stability , 1997 .

[228]  G. Konopka,et al.  Mechanism and prevention of neurotoxicity caused by β-amyloid peptides: relation to Alzheimer's disease , 1997, Brain Research.

[229]  Virginia M. Y. Lee,et al.  Lithium Reduces Tau Phosphorylation by Inhibition of Glycogen Synthase Kinase-3* , 1997, The Journal of Biological Chemistry.

[230]  D. Walker,et al.  Localization of perlecan (or a perlecan‐related macromolecule) to isolated microglia in vitro and to microglia/macrophages following infusion of beta‐amyloid protein into rodent hippocampus , 1997, Glia.

[231]  N. Inestrosa,et al.  Acetylcholinesterase promotes the aggregation of amyloid-beta-peptide fragments by forming a complex with the growing fibrils. , 1997, Journal of molecular biology.

[232]  G. Perry,et al.  Iron accumulation in Alzheimer disease is a source of redox-generated free radicals. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[233]  C. Masters,et al.  Distinct sites of intracellular production for Alzheimer's disease Aβ40/42 amyloid peptides , 1997, Nature Medicine.

[234]  D. Liebler,et al.  The Reduction of α-Tocopherolquinone by Human NAD(P)H:Quinone Oxidoreductase: The Role of α-Tocopherolhydroquinone as a Cellular Antioxidant , 1997 .

[235]  George B. Benedek,et al.  Kinetic theory of fibrillogenesis of amyloid β-protein , 1997 .

[236]  J. Ávila,et al.  Lithium inhibits Alzheimer's disease‐like tau protein phosphorylation in neurons , 1997, FEBS letters.

[237]  M. Verbeek,et al.  Differences between the pathogenesis of senile plaques and congophilic angiopathy in Alzheimer disease. , 1997, Journal of Neuropathology and Experimental Neurology.

[238]  C. Olanow,et al.  Oxidative stress and the pathogenesis of Parkinson's disease , 1996, Neurology.

[239]  M. Emmerling,et al.  Morphology and Toxicity of Aβ-(1-42) Dimer Derived from Neuritic and Vascular Amyloid Deposits of Alzheimer's Disease* , 1996, The Journal of Biological Chemistry.

[240]  Patrick L. McGeer,et al.  Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer's disease , 1996, Neurology.

[241]  Claudia Linker,et al.  Acetylcholinesterase Accelerates Assembly of Amyloid-β-Peptides into Alzheimer's Fibrils: Possible Role of the Peripheral Site of the Enzyme , 1996, Neuron.

[242]  H. Naiki,et al.  First-order kinetic model of Alzheimer's beta-amyloid fibril extension in vitro. , 1996, Laboratory investigation; a journal of technical methods and pathology.

[243]  G. Drewes,et al.  Structure, Microtubule Interactions, and Phosphorylation of Tau Protein a , 1996, Annals of the New York Academy of Sciences.

[244]  R. Wurtman,et al.  Amyloid precursor protein processing is stimulated by metabotropic glutamate receptors. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[245]  C. Masters,et al.  Characterization of the high affinity heparin binding site of the Alzheimer's disease βA4 amyloid precursor protein (APP) and its enhancement by zinc(II) , 1995, Journal of molecular recognition : JMR.

[246]  T. Wight,et al.  Differential binding of vascular cell-derived proteoglycans (perlecan, biglycan, decorin, and versican) to the beta-amyloid protein of Alzheimer's disease. , 1995, Archives of biochemistry and biophysics.

[247]  P. Hof,et al.  Neurofibrillary degeneration in amyotrophic lateral sclerosis/parkinsonism-dementia complex of Guam. Immunochemical characterization of tau proteins. , 1995, The American journal of pathology.

[248]  J. Pettegrew,et al.  Development of small molecule probes for the Beta-amyloid protein of Alzheimer's Disease , 1994, Neurobiology of Aging.

[249]  Khadija Iqbal,et al.  Role of abnormally phosphorylated tau in the breakdown of microtubules in Alzheimer disease. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[250]  Gastone G. Celesia,et al.  A 30-Week Randomized Controlled Trial of High-Dose Tacrine in Patients With Alzheimer's Disease , 1994 .

[251]  P. Solomon,et al.  A 30-week randomized controlled trial of high-dose tacrine in patients with Alzheimer's disease. The Tacrine Study Group. , 1994, JAMA.

[252]  R. Kalaria,et al.  Heparan sulfate proteoglycan in diffuse plaques of hippocampus but not of cerebellum in Alzheimer's disease brain. , 1994, The American journal of pathology.

[253]  R. Benecke,et al.  Electron transfer complexes I and IV of platelets are abnormal in Parkinson's disease but normal in Parkinson-plus syndromes. , 1993, Brain : a journal of neurology.

[254]  R. Rodnitzky,et al.  Histological and biochemical pathology in a family with autosomal dominant Parkinsonism and dementia , 1993 .

[255]  K. Brunden,et al.  pH‐Dependent Binding of Synthetic β‐Amyloid Peptides to Glycosaminoglycans , 1993 .

[256]  Khadija Iqbal,et al.  Microtubule-associated protein tau. Abnormal phosphorylation of a non-paired helical filament pool in Alzheimer disease. , 1993, The Journal of biological chemistry.

[257]  P. Lansbury,et al.  Seeding “one-dimensional crystallization” of amyloid: A pathogenic mechanism in Alzheimer's disease and scrapie? , 1993, Cell.

[258]  Brian J Cummings,et al.  Localization of heparan sulfate glycosaminoglycan and proteoglycan core protein in aged brain and Alzheimer's disease , 1992, Neuroscience.

[259]  Barry Halliwell,et al.  Reactive Oxygen Species and the Central Nervous System , 1992, Journal of neurochemistry.

[260]  P. Fraser,et al.  Effects of Sulfate Ions on Alzheimer β/A4 Peptide Assemblies: Implications for Amyloid Fibril‐Proteoglycan Interactions , 1992, Journal of neurochemistry.

[261]  A. Hyman,et al.  Modulation of the dynamic instability of tubulin assembly by the microtubule-associated protein tau. , 1992, Molecular biology of the cell.

[262]  E. Love,et al.  Parkinson's disease and exposure to agricultural work and pesticide chemicals , 1992, Neurology.

[263]  J. Hardy,et al.  Alzheimer's disease: the amyloid cascade hypothesis. , 1992, Science.

[264]  M. Pangalos,et al.  Treatment strategies for Alzheimer's disease , 1992, The Lancet.

[265]  C. Barrow,et al.  Solution structures of beta peptide and its constituent fragments: relation to amyloid deposition. , 1991, Science.

[266]  V. Wheaton,et al.  Molecular cloning of a functional thrombin receptor reveals a novel proteolytic mechanism of receptor activation , 1991, Cell.

[267]  M. Goedert,et al.  Expression of separate isoforms of human tau protein: correlation with the tau pattern in brain and effects on tubulin polymerization. , 1990, The EMBO journal.

[268]  J. Parks,et al.  Abnormalities of the electron transport chain in idiopathic parkinson's disease , 1989, Annals of neurology.

[269]  R. A. Crowther,et al.  Multiple isoforms of human microtubule-associated protein tau: sequences and localization in neurofibrillary tangles of Alzheimer's disease , 1989, Neuron.

[270]  Y. Kagawa,et al.  Deficiencies in complex I subunits of the respiratory chain in Parkinson's disease. , 1989, Biochemical and biophysical research communications.

[271]  C. Wischik.  Cell biology of the Alzheimer tangle. , 1989, Current opinion in cell biology.

[272]  P. Mcgeer,et al.  Reactive microglia are positive for HLA‐DR in the substantia nigra of Parkinson's and Alzheimer's disease brains , 1988, Neurology.

[273]  H. Braak,et al.  Argyrophilic grains: characteristic pathology of cerebral cortex in cases of adult onset dementia without Alzheimer changes , 1987, Neuroscience Letters.

[274]  G. Campanella,et al.  Ecogenetics of Parkinson's Disease: Prevalence and Environmental Aspects in Rural Areas , 1987, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.

[275]  L. Autilio‐Gambetti,et al.  Paired helical filaments from Alzheimer disease patients contain cytoskeletal components. , 1985, Proceedings of the National Academy of Sciences of the United States of America.

[276]  R. Bartus,et al.  The cholinergic hypothesis of geriatric memory dysfunction. , 1982, Science.

[277]  G. Cohen,et al.  Coupling of Dopamine Oxidation (Monoamine Oxidase Activity) to Glutathione Oxidation Via the Generation of Hydrogen Peroxide in Rat Brain Homogenates , 1981, Journal of neurochemistry.

[278]  D. Graham.  Oxidative pathways for catecholamines in the genesis of neuromelanin and cytotoxic quinones. , 1978, Molecular pharmacology.

[279]  P. Davies,et al.  SELECTIVE LOSS OF CENTRAL CHOLINERGIC NEURONS IN ALZHEIMER'S DISEASE , 1976, The Lancet.

[280]  Katunina Ea,et al.  [Epidemiology of Parkinson's disease]. , 2013, Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova.

[281]  Dong Jin Kim,et al.  Multivalent & multifunctional ligands to beta-amyloid. , 2009, Current pharmaceutical design.

[282]  J. Hardy,et al.  The Amyloid Hypothesis of Alzheimer ’ s Disease : Progress and Problems on the Road to Therapeutics , 2009 .

[283]  Ikuko Miyazaki,et al.  Dopamine- or L-DOPA-induced neurotoxicity: The role of dopamine quinone formation and tyrosinase in a model of Parkinson’s disease , 2009, Neurotoxicity Research.

[284]  R. Glockshuber,et al.  Amyloid-beta aggregation. , 2007, Neuro-degenerative diseases.

[285]  L. Mucke,et al.  PKCepsilon increases endothelin converting enzyme activity and reduces amyloid plaque pathology in transgenic mice. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[286]  I. Ferrer,et al.  Amyloid- (cid:1) Peptide Remnants in AN-1792-Immunized Alzheimer’s Disease Patients A Biochemical Analysis , 2006 .

[287]  D. Price,et al.  Parkinson's disease alpha-synuclein transgenic mice develop neuronal mitochondrial degeneration and cell death. , 2006, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[288]  D. Teplow,et al.  On the nucleation of amyloid beta-protein monomer folding. , 2005, Protein science : a publication of the Protein Society.

[289]  Jianpeng Ma,et al.  Conformational transition of amyloid beta-peptide. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[290]  H. Braak,et al.  Neuropathology of Alzheimer’s Disease , 2004 .

[291]  B. Ibach,et al.  Acetylcholinesterase inhibition in Alzheimer's Disease. , 2004, Current pharmaceutical design.

[292]  G. Powis,et al.  Mitomycin C is not metabolized by but is an inhibitor of human kidney NAD(P)H:(quinone-acceptor)oxidoreductase , 2004, Cancer Chemotherapy and Pharmacology.

[293]  R. Berry,et al.  Conformational changes and truncation of tau protein during tangle evolution in Alzheimer's disease. , 2003, Journal of Alzheimer's disease : JAD.

[294]  C. Masters,et al.  Copper, beta-amyloid, and Alzheimer's disease: tapping a sensitive connection. , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[295]  A. Schapira,et al.  Genetic and environmental factors in the cause of Parkinson's disease , 2003, Annals of neurology.

[296]  T. Bayer,et al.  Alzheimer beta-amyloid homodimers facilitate A beta fibrillization and the generation of conformational antibodies. , 2003, The Journal of biological chemistry.

[297]  D. Sulzer,et al.  The neuromelanin of human substantia nigra: structure, synthesis and molecular behaviour. , 2003, Journal of neural transmission. Supplementum.

[298]  J. Flier,et al.  The neuroprotective antioxidant alpha-lipoic acid induces detoxication enzymes in cultured astroglial cells. , 2002, Free radical research.

[299]  Patrik Brundin,et al.  Pathogenesis of Parkinson's disease: dopamine, vesicles and alpha-synuclein. , 2002, Nature reviews. Neuroscience.

[300]  J. Cano,et al.  The degenerative effect of a single intranigral injection of LPS on the dopaminergic system is prevented by dexamethasone, and not mimicked by rh-TNF-alpha, IL-1beta and IFN-gamma. , 2002, Journal of neurochemistry.

[301]  M. Kirkitadze,et al.  Amyloid beta -protein (Abeta) assembly: Abeta 40 and Abeta 42 oligomerize through distinct pathways. , 2002 .

[302]  M. Tabaton,et al.  Full length alpha-synuclein is present in cerebrospinal fluid from Parkinson's disease and normal subjects. , 2000, Neuroscience letters.

[303]  G. Wilcock,et al.  Efficacy and safety of galantamine in patients with mild to moderate Alzheimer's disease: multicentre randomised controlled trial. Galantamine International-1 Study Group. , 2000, BMJ.

[304]  F. Gejyo,et al.  Kinetic analysis of amyloid fibril formation. , 1999, Methods in enzymology.

[305]  P. Fraser,et al.  A sulfated proteoglycan aggregation factor mediates amyloid-beta peptide fibril formation and neurotoxicity. , 1999, Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis.

[306]  E. Sulkowski,et al.  Alzheimer's beta-amyloid peptide: affinity for metal chelates. , 1998, Journal of Peptide Research.

[307]  P. Libby,et al.  Generation of biologically active IL-1 beta by matrix metalloproteinases: a novel caspase-1-independent pathway of IL-1 beta processing. , 1998, Journal of immunology.

[308]  T. Wight,et al.  Perlecan binds to the beta-amyloid proteins (A beta) of Alzheimer's disease, accelerates A beta fibril formation, and maintains A beta fibril stability. , 1997, Journal of neurochemistry.

[309]  M G Spillantini,et al.  Alpha-synuclein in Lewy bodies. , 1997, Nature.

[310]  D. Kirschner,et al.  Kinetic theory of fibrillogenesis of amyloid beta-protein. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[311]  G. Konopka,et al.  Mechanism and prevention of neurotoxicity caused by beta-amyloid peptides: relation to Alzheimer's disease. , 1997, Brain research.

[312]  D. Liebler,et al.  The reduction of alpha-tocopherolquinone by human NAD(P)H: quinone oxidoreductase: the role of alpha-tocopherolhydroquinone as a cellular antioxidant. , 1997, Molecular pharmacology.

[313]  M. Zigmond,et al.  Loss of dopaminergic neurons in parkinsonism: possible role of reactive dopamine metabolites. , 1997, Journal of neural transmission. Supplementum.

[314]  M. Emmerling,et al.  Water-soluble Abeta (N-40, N-42) oligomers in normal and Alzheimer disease brains. , 1996, The Journal of biological chemistry.

[315]  J. W. Francis,et al.  Neuroglial responses to the dopaminergic neurotoxicant 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mouse striatum. , 1995, Neurotoxicology and teratology.

[316]  J. W. Francis,et al.  Neuroglial Responses to the Dopaminergic Neurotoxicant , 1995 .

[317]  C. Behl,et al.  Hydrogen peroxide mediates amyloid beta protein toxicity. , 1994, Cell.

[318]  K. Brunden,et al.  pH-dependent binding of synthetic beta-amyloid peptides to glycosaminoglycans. , 1993, Journal of neurochemistry.

[319]  A. Alzheimer.  A contribution concerning the pathological anatomy of mental disturbances in old age, 1899. , 1991, Alzheimer Disease and Associated Disorders.

[320]  Hans Förstl,et al.  A Contribution Concerning the Pathological Anatomy of Mental Disturbances in Old Age , 1991 .

[321]  S. Fahn.  Adverse Effects of Levodopa in Parkinson’s Disease , 1989 .